Fuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsight
31. Juli 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 31, 2024 (GLOBE NEWSWIRE) -- Fuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsight The market for Fuchs...
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
29. Januar 2019 08:30 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
23. April 2018 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled.The trial is on track to announce interim six-month data on...